Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
based case » base case (Expand Search), based cancer (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 161 - 180 results of 89,544 for search '(( significant based case ) OR ( significant ((nn decrease) OR (a decrease)) ))', query time: 1.41s Refine Results
  1. 161
    Fig 5 -

    Fig 5 - by Xiaoqing Chen (89898)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 162
    The global disease burden of osteoarthritis for both sexes in 204 countries and territories.

    The global disease burden of osteoarthritis for both sexes in 204 countries and territories. by Xiaoqing Chen (89898)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 163
    Base-case analysis.

    Base-case analysis. by Akiko Kowada (14659965)

    Published 2023
    “…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
    Save to List
    Saved in:
  4. 164
    LPS administration demonstrated a significant decrease in the protein expression of both claudin-1 and occludin in BF fed mice as compared to control mice.

    LPS administration demonstrated a significant decrease in the protein expression of both claudin-1 and occludin in BF fed mice as compared to control mice. by Valentina Di Caro (510473)

    Published 2019
    Save to List
    Saved in:
  5. 165
    Bacterial groups that showed a significantly decreased abundance after antibiotic treatment (AMC and DOX group) compared to the control group (CON group).

    Bacterial groups that showed a significantly decreased abundance after antibiotic treatment (AMC and DOX group) compared to the control group (CON group). by Evangelia M. Stavroulaki (11840809)

    Published 2021
    Save to List
    Saved in:
  6. 166
    Podocyte specific KO of FcRn results in a significant decrease in albuminuria, glomerulosclerosis, and glomerular crescents after nephrotoxic serum nephritis induction.

    Podocyte specific KO of FcRn results in a significant decrease in albuminuria, glomerulosclerosis, and glomerular crescents after nephrotoxic serum nephritis induction. by James F. Dylewski (9922380)

    Published 2020
    “…Podocyte-specific KO of FcRn results in a significant decrease in the number of crescents (p = 0.0007).…”
    Save to List
    Saved in:
  7. 167
    Podocyte specific KO of FcRn results in a significant decrease in glomerular crescents 8 days after anti-GBM disease induction.

    Podocyte specific KO of FcRn results in a significant decrease in glomerular crescents 8 days after anti-GBM disease induction. by James F. Dylewski (9922380)

    Published 2020
    “…Podocyte-specific KO of FcRn results in a significant decrease in the number of crescents (a, p = 0.035).…”
    Save to List
    Saved in:
  8. 168
    HPV16 E1 decreases cell growth.

    HPV16 E1 decreases cell growth. by Fern Baedyananda (11888703)

    Published 2021
    Save to List
    Saved in:
  9. 169
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 170
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 171
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 172
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 173
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 174
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 175
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 176
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 177
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 178
    Data set for study.

    Data set for study. by Aiman Aslam (15213610)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 179
    Summary of patient characteristics.

    Summary of patient characteristics. by Aiman Aslam (15213610)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 180
    Genetic test outcome for all patients and family history breakdown for patients with negative genetic results.

    Genetic test outcome for all patients and family history breakdown for patients with negative genetic results. by Aiman Aslam (15213610)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: